NCT06993610Phase 2Active not recruiting

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

Study sponsor: Zura Bio Inc

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-09-18Actual
Enrollment · participants247Actual
Source updated2026-10-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 225 participants (planned). After: 247 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Nov 2026. After: 18 Sep 2026.

Check registry source

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 2 fields changed

Planned enrollment increased by 45 participants

Before: 180 participants (planned). After: 225 participants (planned).

Primary completion date changed

Before: Sep 2026. After: Nov 2026.

Check registry source

· 1 field changed

Planned enrollment decreased by 45 participants

Before: 225 participants (planned). After: 180 participants (planned).

Check registry source

· 1 field changed

Planned enrollment increased by 45 participants

Before: 180 participants (planned). After: 225 participants (planned).

Check registry source